European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors (TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast, adverse events (AEs) are often reported as infrequent, minor, tolerable and manageable, but they are increasingly important...

詳細記述

保存先:
書誌詳細
出版年:Leukemia
主要な著者: Steegmann, J L, Baccarani, M, Breccia, M, Casado, L F, García-Gutiérrez, V, Hochhaus, A, Kim, D-W, Kim, T D, Khoury, H J, Le Coutre, P, Mayer, J, Milojkovic, D, Porkka, K, Rea, D, Rosti, G, Saussele, S, Hehlmann, R, Clark, R E
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 2016
主題:
Review
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4991363/
https://ncbi.nlm.nih.gov/pubmed/27121688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.104
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料